Analyzing Cost of Revenue: Perrigo Company plc and Iovance Biotherapeutics, Inc.

Comparing cost strategies of Perrigo and Iovance from 2014-2023.

__timestampIovance Biotherapeutics, Inc.Perrigo Company plc
Wednesday, January 1, 201493357722613100000
Thursday, January 1, 20159990002891500000
Friday, January 1, 20169780003228800000
Sunday, January 1, 20179520002966700000
Monday, January 1, 20189560002900200000
Tuesday, January 1, 201981229993064100000
Wednesday, January 1, 202087120003248100000
Friday, January 1, 2021139800002722500000
Saturday, January 1, 2022211350002996200000
Sunday, January 1, 2023107550002975200000
Loading chart...

Cracking the code

Analyzing Cost of Revenue: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding cost structures is crucial. Perrigo Company plc, a stalwart in the pharmaceutical industry, consistently reported a cost of revenue averaging around $2.96 billion annually from 2014 to 2023. This stability reflects its robust market presence and operational efficiency. In contrast, Iovance Biotherapeutics, Inc., a rising star in biotechnology, exhibited a more dynamic cost pattern. Starting with a modest $952,000 in 2017, Iovance's cost of revenue surged by over 2,000% to approximately $21 million by 2022. This dramatic increase underscores its aggressive growth strategy and investment in innovative therapies. The juxtaposition of these two companies highlights the diverse financial strategies within the industry, offering valuable insights for investors and stakeholders alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025